default author photo

Noemi Afonso

Universidade do Porto - Centro Hospitalar

Rua Dr. Roberto Frias

4200-464 Porto

Portugal

SCHOLARLY PAPERS

1

DOWNLOADS

76

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Chemotherapy De-Escalation Using an 18F-FDG PET/CT–Based, Pathologic Response–Adapted Strategy in HER2-Positive Early Breast Cancer: The PHERGain Trial

Number of pages: 38 Posted: 02 Dec 2020
Quiron Group - International Breast Cancer Center (IBCC), Université Libre de Bruxelles (ULB) - Institute Jules Bordet, Hospital Universitario Virgen del Rocío - Medical Oncology Department, Institut Català d'Oncologia, Hospital Clínico Universitario de Valencia, Queen Mary University of London - Barts ECMC, Leitung Sektion Translationale Gynäkologische Onkologie Nationales Centrum für 27 Tumorerkrankungen und Universitätsfrauenklinik Heidelberg, Vall d'Hebron University Hospital - Breast Cancer Group, Hospital Universitario A Coruña - UGC Oncología Intercentros, Hospital Universitario Virgen de la Victoria, Universidad de Alcalá, IRYCIS, Hospital Universitari Sant Joan de Reus - Department of Medical Oncology, Hospital Clinic of Barcelona - Department of Medical Oncology, Institut Claudius Regaud - IUCT-Oncopole, CRCT, Inserm, Sorbonne University - Tenon Hospital, Nuclear Medicine and PET Center Department, European Institute of Oncology (IEO) - Division of Medical Senology, Universidade do Porto - Centro Hospitalar, Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Vall d'Hebron Institute of Oncology, Universidad Catolica - Hospital Arnau de Vilanova and Independent
Downloads 76 (830,555)

Abstract:

Loading...

Trastuzumab; Pertuzumab; De-escalation; Pathologic complete response; FDG-PET/CT; HER2-positive; Early breast cancer